(A19_067_2015_0670001_1014) A19_067_2015_0670001_1014 (Q2167226)
Jump to navigation
Jump to search
Project Q2167226 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | (A19_067_2015_0670001_1014) A19_067_2015_0670001_1014 |
Project Q2167226 in Italy |
Statements
90,850.0 Euro
0 references
181,700.0 Euro
0 references
50.0 percent
0 references
6 June 2015
0 references
13 May 2019
0 references
22 March 2021
0 references
PHARMA QUALITY EUROPE SRL
0 references
43°46'11.53"N, 11°15'20.09"E
0 references
IL PROGETTO MIRA A SUPERARE CRITICIT? TECNOLOGICHE NELLO SVILUPPO DI NUOVE STRATEGIE DIAGNOSTICHE E TERAPEUTICHE PER PATOLOGIE A ELEVATO IMPATTO SOCIALE, COME MELANOMA E SCLEROSI MULTIPLA. L?IDEA SI BASA SULLO SVILUPPO DI NUOVE TECNICHE DI INGEGNERIZZAZIONE CELLULARE E/O SUL TARGETING SELETTIVO MEDIATO DA NANOCARRIER E SI FOCALIZZA SULLO SFRUTTAMENTO DELLE PROPRIET? MULTIMODALI DI QUESTI COSTRUTTI, SUL LORO ACCUMULO NEI TESSUTI D?INTERESSE O PER RICONOSCIMENTO SELETTIVO DI UNIT? TARGETING O VIA INTERNALIZZAZIONE IN CELLULE DEL SISTEMA IMMUNITARIO, SULLA LORO CAPACIT? DI FUNZIONARE COME AGENTI DI CONTRASTO PER IMAGING E DI ESSERE ATTIVATI DA CAMPI MAGNETICI A BASSA FREQUENZA E/O IMPULSI LASER, FUNZIONANDO DA MEDIATORI IPERTERMICI. NEGLI ULTIMI ANNI CERICOL HA PROGREDITO NEL SUPERAMENTO DELLO STATO DELL?ARTE SVILUPPANDO UNA TECNICA INNOVATIVA, PERSONALIZZABILE SUL SINGOLO PAZIENTE E APPLICABILE AI FINI DIAGNOSTICI E TERAPEUTICI CON NOTEVOLE SPECIFICIT? PER DIVERSE PATOLOGIE. NEL PRESENTE (Italian)
0 references
DOES THE PROJECT AIM AT OVERCOMING CRITICAL? TECHNOLOGICAL IN THE DEVELOPMENT OF NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES FOR DISEASES WITH HIGH SOCIAL IMPACT, SUCH AS MELANOMA AND MULTIPLE SCLEROSIS. DOES THE IDEA RELY ON THE DEVELOPMENT OF NEW TECHNIQUES FOR CELL ENGINEERING AND/OR SELECTIVE TARGETING BY NANOCARRIER AND FOCUS ON EXPLOITATION OF PROPRIET RESOURCES? MULTIMODAL OF THESE CONSTRUCTS, ON THEIR ACCUMULATION IN TISSUE D? INTEREST OR FOR SELECTIVE RECOGNITION OF UNITS? TARGETING OR INTERNALISATION IN CELLS OF THE IMMUNE SYSTEM, ABOUT THEIR UNDERSTANDING? TO OPERATE AS CONTRAST IMAGING AGENTS AND TO BE OPERATED BY LOW FREQUENCY MAGNETIC FIELDS AND/OR LASER PULSES, AS RUN BY THE IPERTERMBICI MEDIATORS. IN THE LAST FEW YEARS, CERCOL HAS MADE PROGRESS IN SURPASSING THE STATE OF THE ART BY DEVELOPING AN INNOVATIVE TECHNIQUE, WHICH CAN BE CUSTOMISABLE ON THE INDIVIDUAL PATIENT AND WHICH IS APPLICABLE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES WITH A HIGH LEVEL OF SPECIFIC ICIT? FOR VARIOUS DISEASES. IN THE PRESENT (English)
0 references
Identifiers
D56G15001390009
0 references